Show simple item record

National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study

dc.contributor.authorJessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff
dc.date.accessioned2022-01-21T08:46:00Z
dc.date.available2022-01-21T08:46:00Z
dc.date.issued2021
dc.identifier.urihttps://repository.maseno.ac.ke/handle/123456789/4436
dc.descriptionhttps://doi.org/10.1016/j.vaccine.2021.11.009en_US
dc.description.abstractCurrently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) where rotavirus disease burden is highest. Next-generation rotavirus vaccine (NGRV) candidates in development may have a greater public health impact where they are needed most. The feasibility and acceptability of possible new rotavirus vaccines were explored as part of a larger public health value proposition for injectable NGRVs in LMICs.en_US
dc.description.sponsorshipPATH, Seattle, 2201 Westlake Ave, Seattle, WA 98121, USA b PATH, Ghana, PMB CT 307 Cantonments Accra, Ghana c PATH, India, 15th Floor, Dr. Gopal Das Bhawan 28, Barakhamba Road, Connaught Place, New Delhi 110001, India d Department of Pediatrics, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka e PATH, Malawi, Private Bag B381 Capital City, Lilongwe 3, Malawi f PATH, Kenya, ACS Plaza, 4th Floor Lenana and Galana Road, P.O. Box 76634-00508, Nairobi, Kenya g PATH Senegal Consultant, Fann Résidence Rue Saint John Perse X F Dakar, Senegal h PATH, Washington, DC, 455 Massachusetts Ave. NW, Suite 1000, Washington, DC 20001, USA i Université Libre de Bruxelles, Brussels, Belgiumen_US
dc.publisherElsevieren_US
dc.subjectRotavirusRotavirus vaccinesNext-generation rotavirus vaccinesValue propositionNew vaccine introductionVaccine decision-makingen_US
dc.titleNational stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country studyen_US
dc.typeArticleen_US


Files in this item

Thumbnail
Name:
o.pdf
Size:
1.235Mb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record